Immune cells take on head and neck cancer in early trial
NCT ID NCT06236425
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This early-phase study tests a new treatment for people with advanced head and neck cancer that has spread or come back. The treatment uses a patient's own immune cells (called TILs) that are grown in a lab and given back along with an immunotherapy drug (pembrolizumab). The main goal is to see if this combination is safe and tolerable for 7 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.